

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. **Applicant's submission filed on 11/22/2010 has been entered.**

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Ms. Janet A. Cord, on 4/29/2011.

Examiner's Amendment to the Claims

Cancel claims 45-46, 50-51 and 62.

In claim 37, line 2, after "said polypeptide", delete "comprising" and substitute therefor --
- consisting of ---.

In claim 37, line 4, after "which is " delete " close to" and substitute therefor --- between
80%-90% of ----.

In claim 40, line 2, after "DELTA.Prx", delete "V1hum" and substitute therefor --- Prx
V1hum ---.

In claim 40, line 6, after "DELTA.Prx", delete "V1hum" and substitute therefor --- Prx V1hum ---.

In claim 42, lines 1-6, delete "for enhancing the antioxidant protection from pathology-inducing exogenous and/or endogenous factors selected from the group consisting of: a) bacterial or viral infection, b) action of thermal and chemical factors; burn, frostbite; c) mechanical injuries: wounds, fractures, concussions; d) exposure to ionizing and non-ionizing radiation, containing a clinically efficacious amount of peroxiredoxin Prx V1hum, "and substitute therefor --- comprising ----.

In claim 42, line 7, before "as defined in ...", delete "Prx V1hum", and substitute therefor --- Prx V1hum ---.

In claim 42, line 7, after "claim", delete "1", and substitute therefor --- 37 ---.

In claim 42, line 9, delete "a) peroxiredoxin Prx V1hum";.

In claim 42, line 10, delete "b)" and substitute therefor --- a) ---.

In claim 42, line 11, delete " c) peroxiredoxin Prx V1hum and dihydrolipoic acid";.

In claim 42, line 12, delete "d)" fragment DELTA of Prx V1hum and dihydrolipoic acid".

In claim 42, line 13, delete "e)", and substitute therefor --- b) ---.

In claim 42, lines 13-14, delete "and dihydrolipoic acid".

In claim 43, line 2, after "DELTA.Prx", delete "V1hum" and substitute therefor --- V1hum ---.

In claim 44, line 2, after "Prx", delete "Prx V1hum", and substitute therefor --- Prx V1hum ---.

Examiner's Amendments to the Specification

In page 1, underneath the title insert the following:

--- This application is the National Stage entry of PCT/RU03/00473, filed 11/5/2003, which claims priority to Russian application Numbers: 2002129774 and 2003123534, filed 11/10/2002 and 7/29/2003, respectively. ---.

The following is an **Examiner's Statement of Reasons for Allowance**:

Claims 37-40, 42-44 and 63-64 are directed to a nucleic acid encoding a polypeptide consisting of a specific fragment of human peroxiredoxin VI, namely peroxiredoxin Prx VIhum, of specific amino acid composition which, surprisingly, has very similar antioxidant activity to that of said full length peroxiredoxin VI, vectors and host cells comprising said product, a method of expressing said product and a pharmaceutical composition comprising the expression product of said nucleic acid.

Claimed nucleic acid is free of prior art. Further, the prior art fails to suggest such specifically claimed nucleic acid. Hence, said product is also non-obvious. Since said nucleic acid is both novel and non-obvious, vectors and host cells comprising said product, a method of expressing said product and a pharmaceutical composition comprising the expression product of said nucleic acid are also novel and non-obvious.

Claims 37-40, 42-44 and 63-64 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARYAM MONSHIPOURI whose telephone number is (571)272-0932. The examiner can normally be reached on full flex.

Serial Number:10/534,238

Art Unit 1656

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Rao Munjunath can be reached on (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Maryam Monshipouri/

Primary Examiner, Art Unit 1656

Application/Control Number: 10/534,238
Art Unit: 1656

Page 2